Efficacy and safety of iris-supported phakic lenses (Verisyse) for the treatment of high myopia: 5-year results
International Ophthalmology, cilt.41, sa.8, ss.2837-2845, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 41 Sayı: 8
- Basım Tarihi: 2021
- Doi Numarası: 10.1007/s10792-021-01841-x
- Dergi Adı: International Ophthalmology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
- Sayfa Sayıları: ss.2837-2845
- Anahtar Kelimeler: Endothelial cell loss, High myopia, Phakic intraocular lenses, Verisyse
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: Evaluating efficacy and safety of iris-supported phakic lenses (Verisyse) for high myopia treatment. Methods: Patients treated with Verisyse (Abbott Medical Optics, Santa Ana, CA, USA) intraocular lens (IOL) implants were evaluated retrospectively. Patients with follow-up periods of more than 5 years were included in the study. Pre- and postoperative fifth-year spheric equivalent (SE) of manifest refraction values, uncorrected and corrected distance visual acuities (UDVA and CDVA, respectively), and endothelial cell density (ECD) values were recorded. Complications were evaluated. Results: Forty-seven eyes of 31 patients were included in the study. Pre- and postoperative fifth year mean SE was − 12.50 ± 3.51D and − 0.72 ± 0.40D, respectively. Pre- and postoperative fifth-year UDVA was 1.56 ± 0.22 and 0.33 ± 0.18 logMAR (p < 0.001), respectively. The safety index (pre- and postoperative CDVA) was 1.39 ± 0.63 at the 5-year follow-up (p > 0,05). The efficacy index (ratio of mean postoperative UDVA to mean preoperative CDVA) of the patients was 1.14 ± 0.60. The mean postoperative endothelial cell loss at 5 years was −7.42%. None of the patients had lost 25% of their preoperative endothelial cells at 5-year follow-up. The mean postoperative endothelial cell loss was −3.05% at 1 year, −1.23% between years one and three, −1.02% between the third and fifth years. Conclusion: Verisyse IOL implantation is an effective and safe for high myopia surgical treatment. However, the 5-year follow-up period is not sufficient to evaluate the safety profiles in terms of endothelial cells.